IRIS

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: A real clinical problem?

ELENA, CHIARA;
2015-01-01
2015
ONCOTARGET
2-s2.0-84946078243
Inglese
6
32
33944
33951
8
26376678
Chronic myeloid leukemia; Dasatinib; Diabetes mellitus; Imatinib; Metabolic syndrome; Nilotinib; Adult; Aged; Aged, 80 and over; Anthropometry; Blood Glucose; C-Peptide; Cohort Studies; Dasatinib; Female; Glucose; Humans; Imatinib Mesylate; Insulin; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Metabolism; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Young Adult; Oncology
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=5580&path%5B%5D=13105
no
12
info:eu-repo/semantics/article
262
Iurlo, Alessandra; Orsi, Emanuela; Cattaneo, Daniele; Resi, Veronica; Bucelli, Cristina; Orofino, Nicola; Sciumè, Mariarita; Elena, Chiara; Grancini, ...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1177806
Citazioni
  • ???jsp.display-item.citation.pmc??? 31
  • Scopus 60
  • ???jsp.display-item.citation.isi??? ND
social impact